Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

Author： Tural Deniz   Batur Sebnem   Erdamar Sibel   Akar Emre   Kepil Nuray   Mandel Nil   Serdengeçti Süheyla  

Publisher： Springer Publishing Company

ISSN： 1010-4283

Source： Tumor Biology, Vol.35, Iss.2, 2014-02, pp. : 1041-1049

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab

By Scartozzi Mario   Giampieri Riccardo   Loretelli Cristian   Mandolesi Alessandra   Prete Michela del   Biagetti Simona   Alfonsi Simona   Faloppi Luca   Bianconi Maristella   Bittoni Alessandro   Bearzi Italo   Cascinu Stefano  

Future Oncology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1207-1214

Future Medicine

Access to resources Recommend Favorite

Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer

By                  

Oncology Letters, Vol. 10, Iss. 4, 2015-01 ,pp. : 2519-2526

Spandidos Publications

Access to resources Recommend Favorite

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

By Soeda Hiroshi   Shimodaira Hideki   Watanabe Mika   Suzuki Takao   Gamoh Makio   Mori Takahiro   Komine Keigo   Iwama Noriyuki   Kato Shunsuke   Ishioka Chikashi  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 670-677

Springer Publishing Company

Access to resources Recommend Favorite

Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab

By Garcia-Albeniz Xabier  

Tumor Biology, Vol. 32, Iss. 2, 2011-04 ,pp. : 417-424

Springer Publishing Company

Access to resources Recommend Favorite

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

By Kishiki Tomokazu   Ohnishi Hiroaki   Masaki Tadahiko   Ohtsuka Kouki   Ohkura Yasuo   Furuse Jyunji   Watanabe Takashi   Sugiyama Masanori  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 749-757

Springer Publishing Company

Access to resources Recommend Favorite